Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit .NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
馬薩諸塞州牛頓，2024 年 11 月 26 日（環球新聞專線）— Acumen 製藥公司 納斯達克股票代碼：ABOS）是一家處於臨床階段的生物製藥公司，該公司正在開發一種針對治療阿爾茨海默氏病的毒性可溶性β澱粉樣低聚物的新療法。該公司今天宣佈，管理層將在美國東部時間2024年12月3日星期二下午3點參加第七屆Evercore ISI HealthConx年度會議的爐邊談話。
The live webcast may be accessed under the Investors tab on and will be archived for 90 days.
可以在 「投資者」 選項卡下觀看網絡直播 並將存檔 90 天。
About Acumen Pharmaceuticals, Inc.
關於 Acumen 製藥公司
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit .
Acumen Pharmaceuticals是一家處於臨床階段的生物製藥公司，正在開發一種針對毒性可溶性β澱粉樣低聚物（AβO）的新療法，用於治療阿爾茨海默氏病（AD）。Acumen的科學創始人開創了對AβOS的研究，越來越多的證據表明AβOS是阿爾茨海默病病理學的早期和持續誘因。繼1期試驗Intercet-AD取得積極結果之後，Acumen目前正專注於推進其候選研究產品sabirnetug（ACU193），這是一種選擇性靶向毒性可溶性AβOS的人源化單克隆抗體，正在進行的針對早期症狀阿爾茨海默氏病患者的2期臨床試驗ALTITUDE-AD（NCT06335173）。該公司總部位於馬薩諸塞州牛頓。欲了解更多信息，請訪問 .
Investors:
Alex Braun
abraun@acumenpharm.com
投資者：
亞歷克斯·布勞恩
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
媒體：
AcumenPR@westwicke.com
